SWOG clinical trial number
S1918

A Phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed diffuse large B cell lymphoma, Grade IIIb Follicular Lymphoma, transformed lymphoma, and high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements

Open
Phase
II-III
Accrual
6%
Abbreviated Title
Ph II/III study of R-miniCHOP +/- oral aza in elderly with newly diganosed DLBCL
Status Notes
Activation - Effective 3/19/21, 12:00 pm Pacific Time

Training for Conduct of FIL Tool, accessible from: https://www.swog.org/required-s1918-training.

Online FIL Tool, accessible from: https://redcap.filinf.it/surveys/?s=RF4FPKH799.

Note: Responses must also be submitted in iMedidata RAVE, as indicated in protocol Section 14.5a, along with the score generated by the online FIL Tool.
Activated
03/19/2021
Participants
ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS LISTED ON TITLE PAGE

Research committees

Lymphoma

Treatment

Cyclophosphamide Prednisone Vincristine Doxorubicin Filgrastim Rituximab Pegfilgrastim CC-486 CHOP

Other Study Materials

Eligibility Criteria Expand/Collapse

* See S1918 protocol Section 5.0; accessible from the CTSU protocol abstract page at www.ctsu.org.

Publication Information Expand/Collapse

2021

S1918: A Phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed diffuse large B cell lymphoma, Grade IIIb Follicular Lymphoma, transformed lymphoma, and high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements

E Brem;H Li;A Beaven;P Caimi;L Cerchietti;A Alizadeh;R Olin;NL Henry;H Dillon;R Little;C Laubach;M LeBlanc;JW Friedberg;S Smith Journal of Geriatric Oncology, Oct 19:S1879-4068(21)00235-6. doi: 10.1016/j.jgo.2021.10.003. Online ahead of print

PMid: PMID34686472

S1918: A Phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed diffuse large B cell lymphoma, Grade IIIb Follicular Lymphoma, transformed lymphoma, and high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements

E Brem;H Li;A Beaven;P Caimi;L Cerchietti;A Alizadeh;R Olin;NL Henry;H Dillon;R Little;C Laubach;M LeBlanc;J Friedberg;S Smith American Society of Hematology (Dec 11-14, 2021, Atlanta, GA), TIPs poster, #3565

Reports & Approvals

Trial Locations

Other Clinical Trials

SWOG Clinical Trial Number
CTSU/ANHL1931

A Randomized Phase 3 trial of Nivolumab (NSC# 748726 IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma.
Research Committee(s)
Lymphoma
Activated
06/07/2021
Open
Phase
SWOG Clinical Trial Number
S1918

A Phase II/III randomized study of R-miniCHOP with or without oral azacitidine (CC-486) in participants age 75 years or older with newly diagnosed diffuse large B cell lymphoma, Grade IIIb Follicular Lymphoma, transformed lymphoma, and high-grade B-cell lymphomas with MYC and BCL2 and/or BCL6 rearrangements
Research Committee(s)
Lymphoma
Activated
03/19/2021
Accrual
6%
Open
Phase
II-III
SWOG Clinical Trial Number
CTSU/EA4181

A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients <= 70 Years Old with Untreated Mantle Cell Lymphoma
Research Committee(s)
Lymphoma
Activated
10/03/2019
Open
Phase
II